SCHEMBL21944998

SCHEMBL21944998

Oc1cc(OC(F)(F)F)cc(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.54
▸ TPX2 Q9ULW0 1/20 0.54
▸ KIF11 P52732 6/20 0.53
▸ PTGS1 P23219 2/20 0.45
▸ PPARD Q03181 3/20 0.44
▸ PPARA Q07869 2/20 0.44
▸ PPARG P37231 1/20 0.44
▸ TRPV1 Q8NER1 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ AKR1C2 P52895 1/20 0.40
▸ AKR1C1 Q04828 1/20 0.40
▸ ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21944789 0.88 AURKA (0.67) AURKATPX2KIF11PPARDNPC1
SCHEMBL21944866 0.86 AURKA (0.45) AURKATPX2KIF11PTGS1TRPV1
SCHEMBL21945512 0.85 AURKA (0.55) AURKATPX2KIF11PTGS1PPARA
SCHEMBL6068041 0.82 KIF11 (0.71) KIF11PTGS1NPC1TP53MAPK1
SCHEMBL1690017 0.80 AURKA (0.71) AURKATPX2KIF11PPARDNPC1
SCHEMBL12952736 0.80 AURKA (0.71) AURKATPX2KIF11PPARDNPC1
SCHEMBL12952783 0.79 AURKA (0.53) AURKATPX2PPARDPPARAPPARG
SCHEMBL21944570 0.78 AURKA (0.48) AURKATPX2ABL1ABCB1BCR
SCHEMBL10989192 0.78 TRPV1 (0.54) AURKATPX2KIF11TRPV1
SCHEMBL18002329 0.76 KIF11 (0.40) AURKATPX2KIF11PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 AURKA 1234/4885TPX2 2721/4885KIF11 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback